



Supplemental Figure S10: Sensitivity of MCF10A cells to two compounds targeting the MAPK signaling pathway.

Treatment with the MAPK inhibitor FR180204 and the RAF1 inhibitor sorafenib over two days showed no significant effects in cells transduced with fusion constructs compared to empty vector controls. Cell viability was measured by MTS assay after 48 hours.